Last reviewed · How we verify
Malaria Challenge
At a glance
| Generic name | Malaria Challenge |
|---|---|
| Sponsor | U.S. Army Medical Research and Development Command |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Pain- solicited local (post-vaccination)
- Headache
- Injection site pain
- Headache- solicited general (post-vaccination)
- Fatigue
- Fatigue (post-vaccination)
- Redness (post-vaccination)
- Chills (post-vaccination)
- Injection site erythema
- Malaria (post-challenge)
- Swelling (post-vaccination)
- Injection site swelling
Key clinical trials
- Clinical Study to Assess Minimum Mosquito Bites for P. Vivax Infection in Thai Adults (NA)
- First-in-Human PfSPZ-LARC2 Vaccination/CHMI (PHASE1)
- Screening of Healthy Volunteers for Investigational Antimalarial Drugs, Malaria Vaccines, and Controlled Human Malaria Challenge
- Safety, Tolerability and Efficacy Against Controlled Human Malaria Infection of PfSPZ-LARC2 Vaccine in Malaria-naïve Adults (PHASE1)
- Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Challenge Agent and Evaluate Transmission in Mosquito Feeding Assays (PHASE1)
- Characterizing Humoral Immune Response to Mosquito Bites (NA)
- Vivax Malaria Human Infection Studies in Thailand (NA)
- A Controlled Human Vivax Malaria Infection Study Through Inoculation of Infected Erythrocytes (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |